U.S. pharmacy policy: A public health perspective on safety and cost

Social Work in Public Health

Volumn 24, Issue 6, 2009, Pages 543-567

  Rosenau, Pauline Vaillancourt ^a   Lal, Lincy S ^b   Glasser, Jay H ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Costs; Direct to consumer advertising; Medication; Pharmacy; Policy; Public health; Safety

Indexed keywords

COST-BENEFIT ANALYSIS; HEALTH EDUCATION; HEALTH POLICY; PUBLIC HEALTH; SAFETY; SAVINGS;

UNITED STATES;

NON PRESCRIPTION DRUG;

ADVERTIZING; ARTICLE; CONSUMER; DRUG COST; DRUG LEGISLATION; DRUG TOXICITY; MANAGEMENT; PUBLIC HEALTH; UNITED STATES;

ADVERTISING AS TOPIC; CONSUMER PARTICIPATION; DRUG COSTS; DRUG TOXICITY; LEGISLATION, DRUG; NONPRESCRIPTION DRUGS; POLICY MAKING; PUBLIC HEALTH; UNITED STATES;

EID: 73449106165     PISSN: 19371918     EISSN: 1937190X     Source Type: Journal    
DOI: 10.1080/19371910802679457     Document Type: Article

References (119)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association, 288(23), 2981-2997.
2. Almasi, E. A., Stafford, R. S., Kravitz, R. L., & Mansfield, P. R. (2006). What are the public health effects of direct-to-consumer drug advertising? Public Library of Science Medicine, 3(3), e145.
3. American Medical Association. (2005, June 14, 2006). AMA calls for temporary moratorium on direct-to-consumer advertising of new prescription drugs. Retrieved June 17, 2006, from http://www.pharmwatch.org/ads/ama.shtml
4. American Medical Association. (2006). Direct-to-consumer advertisements of prescription drugs. Policy finder E-5.015. Retrieved March 3, 2006, from http://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/ code-medicalethics/opinion5015.shtml
5. American Pharmacists Association. (2004). Report of the policy review committee. Washington, DC: Author.
6. American Public Health Association. (1995). Direct-to-consumer prescription drug advertising (Policy Position Paper No. 9516). Washington, DC: Author.
7. American Public Health Association. (1999). Concern about the Food and Drug Administration's drug approval process (Policy Position Paper No. 9915).Washington, DC: Author
8. American Public Health Association. ( 2000). Making medicines affordable: The price factor (Policy Position Paper No. 20006). Washington, DC: Author.
9. American Public Health Association. (2001). Condemnation of pharmaceutical companies retaliatory tactics (Policy Position Paper No. 200126). Washington, DC: Author
10. American Public Health Association. (2003). Supporting legislation for independent post-marketing (phase IV) comparative evaluation of pharmaceuticals (Policy Position Paper No. 20031). Washington, DC: Author.
11. American Public Health Association. (2004). Letter reaffirming support for S. 2328, the Pharmaceutical Market Access and Drug Safety Act of 2004, and expressing concern regarding S. 2493, the Safe IMPORT Act of 2004. Washington, DC: Author.
12. American Public Health Association. (2006). The role of the pharmacist in public health (Policy Position Paper No. 200614). Washington, DC: Author.
13. Medicare Prescription Drug Coverage: Drug Benefits Can Help Senior Citizens Stay Healthy. -Rffrt American Public Health Association. (N.d.). Medicare Prescription Drug Coverage: Drug Benefits Can Help Senior Citizens Stay Healthy. Washington, DC: Author.
14. Anis, A. H., Guh, D. P., Lacaille, D., Marra, C. A., Rashidi, A. A., Li, X., et al. (2005). When patients have to pay a share of drug costs: Effects of frequency of physician visits, hospital admissions and filling of prescriptions. Canadian Medical Association Journal, 173(11), 1335.
15. Annas, G. J. (2004). American bioethics: Crossing human rights and health law. London: Oxford University Press.
16. Avorn, J. (2007). Paying for drug approvals: Who's using whom? The New England Journal of Medicine, 356(17), 1697-1700.
17. Bell, R., Wilkes, M., & Kravitz, R. (2000). The educational value of consumer-targeted prescription drug print advertising. Journal of Family Practice, 49(12), 1092-1098.
18. Bennett, C. L., Nebeker, J. R., Lyons, E. A., Samore, M. H., Feldman, M. D., Mckoy, J. M., et al. (2005). The Research on Adverse Drug Events and Reports (RADAR) Project. Journal of the American Medical Association, 293(17), 2131-2140.
19. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 343(21), 1520-1528.
20. Bowe, C. (2004, November 26). Safety fears plague U.S. drug system. Financial Times. Retrieved from, http://www.ft.com/cms/s/0/e7f7e7ea-3f51-11d9- 8198-00000e2511c8.html
21. Bowe, C. (2006, January 4). U.S. pharmaceutical industry limbers up for Medicare's brave new world. Financial Times. Retrieved from, http://www.ft.com/cms/s/0/a7c60df6-7cc6-11da-936a-0000779e2340.html
22. Bradley, Q. S., Firszt, R., & Eisenberg, M. J. (2005). A comparison of brand-name drug prices between Canadian-based Internet pharmacies and major U.S. drug chain pharmacies. Annals of Internal Medicine, 143(6), 397-404.
23. Brass, E. P. (2001). Changing the status of drugs from prescription to over-the-counter availability. New England Journal of Medicine, 345(11), 810-816.
24. Brewer, T., & Colditz, G. A. (1999). Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs. Journal of the American Medical Association, 281(9), 824-829.
25. Burris, S. (1997). The invisibility of public health: Population-level measures in a politics of market individualism. American Journal of Public Health, 87(10),1607-1610.
26. Calfee, J. E. (2002). Public policy issues in direct-to-consumer advertising for prescription drugs. Journal of Public Policy & Marketing, 21(2), 174-190.
27. Calvillo, J., & Lal, L. (2003). Pilot study of a survey of U.S. residents purchasing medications in Mexico: Demographics, reasons, and types of medications purchased. Clinical Therapeutics, 25(2), 561-577.
28. Carmichael, J. M., O'Connell, M. B., Devine, B., Kelly, W., Ereshefsky, L., Linn, W. D., et al. (1997). Collaborative drug therapy management by pharmacists. Pharmacotherapy, 17(5), 1050-1061.
29. Carpenter, D. (2005). A proposal for financing postmarketing drug safety studies by augmenting FDA user fees. Health Affairs, W5, 469-480.
30. Chan, A. T., Manson, J. E., Feskanich, D., Stampfer, M. J., Colditz, G. A., & Fuchs, C. (2007). Long-term aspirin use and mortality in women. Archives of Internal Medicine, 167, 562-572.
31. Chandler, M. (2006). The rights of the medically uninsured: An analysis of social justice and disparate health outcomes. Journal of Health & Social Policy, 21(3), 17.
32. Chao, B. (2005). Evaluating the educational content of direct-to-consumer fulfillment materials. American Journal of Health System Pharmaceuticals, 62, 620-625.
33. Choudry, N. K., & Detsky, A. S. (2005). A perspective on U.S. drug importation. Journal of the American Medical Association, 293(3), 358-362.
34. Clark, D., Layton, D., & Shakir, S. A. W. (2001). Monitoring the safety of over-thecounter drugs: We need a better way than spontaneous reports. British Medical Journal, 323, 706-707.
35. Cockburn, I. M. (2004). The changing structure of the pharmaceutical industry. Health Affairs, 23(1), 10-22.
36. Cohen, J., Paquette, C., & Cairns, C. P. (2005). Switching prescription drugs to overthecounter. British Medical Journal, 330, 39-41.
37. Committee on the Assessment of the U.S. Drug Safety. (2006). The future of drug safety: Promoting and protecting the health of the public. Washington, DC: The National Academies Press, The Institute of Medicine.
38. Consumer Reports. (2005). Prescription drugs: The facts about Canada. Consumer Reports.
39. Dooren, J. C. (2005, June 1). Drug makers seen as slow to finish postmarket studies. Wall Street Journal.
40. Egilman, D. S., Presler, A. H., & Valentin, C. S. (2007). Avoiding the regulatory capture of the Food and Drug Administration. Archives of Internal Medicine, 167(7), 732-733.
41. Ess, S. M., Schneeweiss, S., & Szucs, T. D. (2003). European health care policies for controlling drug expenditure. Pharmacoeconomics, 21(2), 89-103.
42. FDA Legislative Watch. (2007). PDUFA IV is ''golden opportunity'' to improve drug safety funding and staff [Electronic version]. Retrieved January 1, 2008, from http://www.fdalegislativewatch.com/2007/01/pdufa-iv-is-gol.html.
43. Florida Administrative Code. (1986). Medicinal drugs which may be ordered by pharmacists. Retrieved April 23, 2006, from http://www.flrules.org/Gateway/ View-notice.asp?idD5002986
44. Foege, W. (1987). Public health: Moving from debt to legacy. American Journal of Public Health, 77(10), 1276-1278.
45. Frank, R. (2007). The ongoing regulation of generic drugs. The New England Journal of Medicine, 357(20), 1193-1996.
46. Furberg, C. D., Levin, A. A., Gross, P. A., Shapiro, R. S., & Strom, B. L. (2006). The FDA and drug safety: A proposal for sweeping changes. Archives of Internal Medicine, 166, 1938-1942.
47. Gilbody, S., Wilson, P., & Watt, I. (2005). Benefits and harms of direct-to-consumer advertising: A systematic review. Qual Saf Health Care, 14, 146-250.
48. Gottlieb, S. (2005). Opening Pandora's pillbox: Using modern information tools to improve drug safety. Health Affairs, 24(4), 938-948.
49. Hennessy, S., & Strom, B. L. (2007). PDUFA reauthorization: Drug safety's golden moment of opportunity? The New England Journal of Medicine, 356(17), 1703-1704.
50. Henney, J. E. (1999). International Conference on Surrogate Endpoints and Biomark-ers. Paper presented April 15, 1999, at the International Conference on Surrogate Endpoints, Bethesda, Maryland.
51. Hilts, P. J. (2003). Protecting America's health: The FDA, business, and one hundred years of regulation (1st ed.). New York: Knopf.
52. Hsu, J., Price, M., Huang, J., Brand, R., Fung, V., Hui, R., et al. (2006). Unintended consequences of caps on Medicare drug benefits. New England Journal of Medicine, 354(22), 2349-2359.
53. Huh, J., & Cude, B. (2004). Is the information ''fair and balanced'' in direct-toconsumer prescription drug Web sites? Journal of Health Communities, 9, 529-540.
54. Iglehart, J. K. (2004). The new Medicare prescription drug benefit: A pure power play. New England Journal of Medicine, 350(8), 826-833.
55. Kaiser Family Foundation. (2005). 23 drug companies agree to new guidelines on advertising. Retrieved August 29, 2009, from http://www. kaisernetwork.org/daily-reports/print-report.cfm?DR-IDD31804& dr-catD3.
56. Kaiser Family Foundation. (2006a). FDA does not have effective process for monitoring postmarket drug studies, GAO report says. Retrieved April 27, 2006, from & z.ast;http://www.kaisernetwork.org/daily-reports/rep-index.cfm? hintD3& DR-IDD3 6797.
57. Kaiser Family Foundation. (2006b). Increased bargaining power of bulk prescription drug buyers examined. Retrieved June 22, 2006, from & z.ast;http://www.kaisernet work.org/daily-reports/print-report.cfm?DR- IDD38076& dr-catD3.
58. Kaiser Family Foundation. (2006c). Prescription drug costs: Background brief. Retrieved February 1, 2006, from http://www.kaiseredu.org/topics-im.asp? idD352& parentIDD68& imIDD1.
59. Kaiser Family Foundation. (2006d). Prescriptions drugs: IOM report calls on FDA to improve consumer safety: Recommendations include restrictions on prescription drug advertisements, increased post-market drug reviews. Retrieved from http://www.kaisernetwork.org/daily-reports/print-report.cfm?DR-IDD40015C
60. Lasser, K. E. (2002). Timing of new black box warnings and withdrawals for prescription medications. Journal of the American Medical Association, 287(17), 2215-2220.
61. Levinson, W., & Laupacis, A. (2006). A call for fairness in formulary decisions. Archives of Internal Medicine, 166, 16-18.
62. Lewis, T. R., Reichman, J. H., & So, A. D. (2007). The case for public funding and public oversight of clinical trials [Electronic version]. The Economists' Voice, 4(1), article 3.
63. Lexchin, J., Bero, L., Djulbegovic, B., & Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality. British Medical Journal, 326, 1167-1170.
64. Lexchin, J., & Grootendorst, P. (2004). Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: A systematic review of the evidence. International Journal of Health Services, 34(1), 101-122.
65. Lexchin, J., & Mintzes, B. (2002). Direct-to-consumer advertising of prescription drugs: The evidence says no. Journal of Public Policy & Marketing, 21(2), 194-201.
66. Liebman, A. (2006). Producer's notebook: Spin doctors. Retrieved January 5, 2006, from http://www.pbs.org/wgbh/pages/frontline/shows/prescription/etc/ notebook.html.
67. Light, D. W. (2005). Extraordinary claims require extraordinary evidence. Journal of Health Economics, 24, 1030-1033.
68. Light, D. W. (2007). Misleading congress about drug development. Journal of Health Politics, Policy and Law, 32(5), 895-913.
69. Light, D. W., & Lexchin, J. (2004). Will lower drug prices jeopardize drug research? A policy fact sheet. The American Journal of Bioethics, 4(1), W3-W6.
70. Light, D. W., & Lexchin, J. (2005). Foreign free riders and the high price of U.S. medicines. British Medical Journal, 331, 958-960.
71. Localio, A. R., Lawthers, A., Brennan, T. A., Laird, N. M., Hebert, L. E., Peterson, L. M., et al. (1991). Relation between malpractice claims and adverse events due to negligence: Results of the Harvard Medical Practice Study. New England Journal of Medicine, 325(4), 245-251.
72. Loftus, P. (2007, November 7). Drug ads don't tempt Europe. The Wall Street Journal, p. 1.
73. Lueck, S. (2006, February 6). Tax breaks to boost cost of Bush's health budget. The Wall Street Journal. http://online.wsj.com/article/ SB11391898840965664.html
74. Lueck, S., & Fuhrmans, V. (2006, April 21). Large insurers are big winners in new Medicare benefit. Wall Street Journal, p. B1. Retrieved August 29, 2009, from http://online.wsj.com/article/SB114557429837631796.html.
75. Lyles, A. (2002). Direct marketing of pharmaceuticals to consumers. Annual Review of Public Health, 23, 73-91.
76. Mansfield, P. R., Mintzes, B., Richards, D., & Toop, L. (2005). Direct to consumer advertising. British Medical Journal, 330, 5-6.
77. McClellan, M. (2007). Drug safety reform at the FDA: Pendulum swing or systematic improvement? The New England Journal of Medicine, 356(17), 1700-1702.
78. McGlew, J. (2007). FDA reauthorization expands agency's funding and authority [Electronic version]. Washington Report (ACCP Report), 26. Retrieved January 1, 2008, from http://www.accp.com/report/rpt1007/art05.php.
79. Mintzes, B. (2002). Direct to consumer advertising is medicalising normal human experience. British Medical Journal, 324, 908-909.
80. Mintzes, B. (2006). Direct-to-consumer advertising of prescription drugs in Canada. Toronto, Ontario: Health Council of Canada.
81. Mintzes, B., Barer, M. L., Kravitz, R. L., Bassett, K., Lexchin, J., Kazajian, A., et al. (2003). How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Association Journal, 169(5), 405-412.
82. Mintzes, B., Barer, M. L., Kravitz, R. L., Kazajian, K. B., Lexchin, J., Evans, R. G., et al. (2002). Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: Two-site cross sectional survey. British Medical Journal, 324, 278-279.
83. Morgan, S., Bassett, K., & Mintzes, B. (2004). Outcomes-based drug coverage in British Columbia. Health Affairs, 23(1), 269-347.
84. Nyman, J. A. (2007). American health policy: Cracks in the foundation. Journal of Health Politics, Policy and Law, 32(5), 759-783.
85. Office of Inspector General of the Department of Health and Human Services. (2006). FDA's monitoring of postmarketing study commitments (No.OEI-01-04-00390). Washington, DC: Department of Health and Human Services.
86. Okie, S. (2005a). Safety in numbers: Monitoring risk in approved drugs. New England Journal of Medicine, 352(12), 1173-1176.
87. Okie, S. (2005b). What ails the FDA? New England Journal of Medicine, 352(11), 1063-1066.
88. Okie, S. (2006). Access before approval: A right to take experimental drugs? New England Journal of Medicine, 355(5), 437-440.
89. Parker-Pope, T. (2005, November 22). Health insurers push pill splitting as a way to save money on drugs. The Wall Street Journal. Retrieved from http://online.wsj.com/article/SB113261907027203602-search.html
90. Pearson, S. D., & Rawlins, M. D. (2005). Quality, innovation, and value for money: NICE and the British National Health Service. Journal of the American Medical Association, 294(20), 2618-2623.
91. PhRMA. (2005). PhRMA guiding principles: Direct to consumer advertisements about prescription medicines. Washington, DC: The Pharmaceutical Research and Manufacturers of America.
92. Platt, R., & Ommaya, A. (2005). A beneficial side effect of the Medicare drug benefit. New England Journal of Medicine, 353(26), 2742.
93. Psaty, B., Furberg, C., Ray, W. A., & Weiss, N. (2004). Potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cervastatin and risk of rhabdomyolysis. Journal of the American Medical Association, 292(21), 2622-2631.
94. Ray, W. A., & Stein, M. (2006). Reform of drug regulation: Beyond an independent drug-safety board. New England Journal of Medicine, 354(2), 194-201.
95. Reynolds, T. (2002). Switching from prescription to over-the-counter drugs. Annals of Internal Medicine, 136(2), 177-179.
96. Rice, T. (2002). The economics of health reconsidered (2nd ed.). Chicago: Health Administration Press.
97. Rochon, P., Gurwitz, J. H., Simms, R., Fortin, P., Felson, D., et al. (1994). A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine, 154, 157-163.
98. Rosenau, P. (2003). The competition paradigm: America's romance with conflict, contest, and commerce. Lanham, MD: Rowman & Littlefield.
99. Rosenau, P. V. (2000). Managing medical technology: Lessons for the United States from Quebec and France. International Journal of Health Services, 30(2), 617-639.
100. Rudolf, P. M., & Bernsteing, I. (2004). Counterfeit drugs. New England Journal of Medicine, 350(14), 1384-1386.
101. Scherer, F. (2004). The pharmaceutical industry: Prices and progress. New England Journal of Medicine, 351(9), 927-932.
102. Smith, R. (2005). Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Medicine, 2(5), 364-366.
103. Spencer, J. (2004, June 1). Getting drugs without the doctor: States extend prescription-writing powers to growing range of nonphysicians. Wall Street Journal, p. D1.
104. Steinbrook, R. (2005). Financial conflicts of interest and the Food and Drug Administration's advisory committees. New England Journal of Medicine, 353(2), 116-118.
105. Strom, B. L. (2005). Statins and over-the-counter availability. New England Journal of Medicine, 352(14), 1403-1405.
106. Tamblyn, R., Laprise, R., Hanley, J. A., Abrahamowicz, M., Scott, S., Mayo, N., et al. (2001). Adverse events associated with prescription drug cost-sharing among poor and elderly persons. Journal of the American Medical Association, 285(4), 421-429.
107. Taylor, E. F., Chernew, M., & McLaughlin, C. (2006). Do determinants of Medicare supplemental coverage choice vary by income? Journal of Health & Social Policy, 22(1), 1-13.
108. Thorpe, K. E. (2006). Cost sharing, caps on benefits, and the chronically ill: A policy mismatch. New England Journal of Medicine, 354(22), 2385-2386.
109. Toop, L., Richards, D., Dowell, T., Tilyard, M., Fraser, T., & Arroll, B. (2003). Direct to consumer advertising of prescription drugs in New Zealand: For health or for profit? Retrieved from http://www.voc.otago.ac.nz/zz/ report.pdf.
110. U.S. General Accounting Office. (2002). Prescription drugs: FDA oversight of DTC advertising has limitations. Washington, DC: Author.
111. U.S. Governmental Accountability Office. (2006). Drug safety: Improvement needed in FDA's postmarket decision-making and oversight process (No.GAO-06-402). Washington, DC: Department of Health and Human Services.
112. U.S. Governmental Accountability Office. (2007). Drug safety: FDA needs to further address shortcomings in its postmarket decision-making process. Testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives (No.GAO-07-599T). Washington, DC: Author.
113. U.S. Food and Drug Administration, Department of Health and Human Services. (n.d.). Expanded access and expedited approval of new therapies related to HIV/AIDS. Retrieved April 29, 2006, from http://www.fda.gov/ ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm134331.htm
114. Vaughan, B. (2005). PDUFA IV: Putting the public health first. Yonkers, NY: Consumers Union.
115. Vernon, J. A. (2005). Examining the link between price regulation and pharmaceutical R& D investment. Health Economics, 14, 1-16.
116. Viscusi, W. K., Vernon, J. M., & Harrington, J. E. (2000). Economics of regulation and antitrust (3rd ed.). Cambridge, MA: MIT Press.
117. Vogel, E. (2006, March 2). Board approves regulations allowing Nevadans to acquire prescription drugs from Canada. Las Vegas Review-Journal. Retrieved from http://www.reviewjournal.com/lvrj-home/2006/Mar-02-Thu-2006/news/6146607. html
118. Wood, A. J. J. (2006). A proposal for radical changes in the drug approval process. The New England Journal of Medicine, 355(6), 618-623.
119. Zamiska, N., & Tesoriero, H. (2006, January 26). As Pfizer battles fakes in China, nation's police are uneasy allies. The Wall Street Journal, A1, A12.